-
DMG-PEG2000-NH2 for LNP Linker Workflows
2026-08-17
DMG-PEG2000-NH2 is an NH2-PEG derivative for covalent surface functionalization, liposomal drug delivery linker design, and exploratory lipid nanoparticle (LNP) formulation. This workflow-focused guide explains how to manage amide coupling, siRNA encapsulation studies, formulation screening, and the troubleshooting issues that most often compromise reproducibility.
-
Cefoperazone Sodium Salt: From MIC to Model
2026-08-16
Cefoperazone sodium salt is examined through a comparative, evidence-led framework that connects species-specific MIC interpretation with β-lactamase biology and biliary tract infection research. This guide shows how to use Cefoperazone as a precisely controlled research perturbation rather than treating one susceptibility value as a universal efficacy verdict.
-
BRD4 Inhibitors Sensitize Cells to Erastin Ferroptosis
2026-08-15
A 2024 Discover Oncology study shows that BRD4 inhibition with JQ-1 or I-BET-762 broadly increases erastin-induced ferroptosis across five cell lines. The work identifies reactive oxygen species accumulation and reduced FSP1 expression as shared mechanistic features, while also revealing cell-specific changes in other ferroptosis regulators.
-
Structure-Switching Aptamer for BoNT Detection
2026-08-14
This 2024 BioChip Journal study introduced BOSS-SELEX to identify BoNT-A4, an aptamer that changes conformation when it binds botulinum neurotoxin A. Coupling this recognition element to tyramide signal amplification produced a selective colorimetric assay with nanomolar affinity and a reported detection threshold of 5.72 ng/mL.
-
DiscoveryProbe Bioactive Compound Library Plus
2026-08-14
The DiscoveryProbe Bioactive Compound Library Plus can be used as more than a hit-finding collection: it is a structured perturbation system for connecting ligand binding with cellular mechanism. This guide combines thermal shift assay principles, orthogonal validation, and pathway-focused screening for more defensible discovery decisions.
-
Axitinib Response Phenotyping in Cancer Assays
2026-08-13
Axitinib and AG 013736 can reveal how VEGF pathway blockade changes endothelial signaling, proliferation, and cell fate. This guide applies a response-phenotyping framework to improve angiogenesis inhibition assays and interpret xenograft findings without confusing growth arrest with cell death.
-
α2-AR Agonism in Osteosarcoma Recurrence
2026-08-13
A recent preclinical study examines α2-adrenergic receptor agonism as an immune-based strategy to limit osteosarcoma recurrence after surgery. Its hydrogel delivery approach separates direct tumor-cell effects from immune-mediated activity and identifies CD8+ T-cell, TCR, and ITGAL-associated mechanisms for further investigation.
-
GSK2606414: Precision PERK Inhibition in ER Stress
2026-08-12
GSK2606414 is a potent, selective PERK inhibitor for separating PERK-dependent signaling from broader ER stress effects. This article translates recent TMAO–NAFLD findings into practical cell, tissue, and disease-model workflows, with dose planning and troubleshooting guidance.
-
Axitinib Workflow for VEGF Response Assays
2026-08-12
Build more informative angiogenesis inhibition assays with Axitinib (AG 013736) by pairing VEGFR pathway readouts with separate measures of proliferation and cell death. This workflow emphasizes solvent control, time-resolved dosing, orthogonal validation, and careful translation from endothelial models to xenograft research.
-
MDL 28170: Calpain Control in Neuroprotection
2026-08-11
MDL 28170 is a cell-permeable calpain inhibitor for dissecting protease-driven neuronal injury, synaptic dysfunction, and apoptosis. This article translates recent BDNF/TrkB findings into assay-selection, interpretation, and cross-model guidance.
-
Elobixibat Hydrate: IBAT Research Workflows
2026-08-11
Elobixibat hydrate provides a compartment-focused way to study how ileal bile acid transport shapes colonic secretion, motility, and gut–metabolic signaling. This practical guide connects formulation, tissue assays, stool and bile acid endpoints, and troubleshooting for constipation, colonoscopy-preparation, and metabolic research.
-
Triamcinolone (B1859) Technical Workflow Guide
2026-08-10
Triamcinolone (B1859) is a synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solubility, storage, controls, and assay QC; the material is for scientific research only and should not be used for diagnostic or clinical applications.
-
2-DG, mTOR, and T-Cell Injury in Oral Lichen Planus
2026-08-09
The reference study identifies glycolytic dependence in oral lichen planus-derived T cells and shows that 2-deoxy-D-glucose reduces their capacity to induce keratinocyte apoptosis. Its pharmacologic combination with Rapamycin links glycolysis, mTOR-associated signaling, T-cell survival, and epithelial injury, providing a useful framework for immunometabolism research.
-
Resiniferatoxin (RTX) Workflow for TRPV1 Research
2026-08-08
Resiniferatoxin (RTX) turns TRPV1 activation into a practical strategy for mapping sensory-neuron function, modeling pain, and testing targeted analgesia. This guide connects calcium-flux assays with route-specific animal workflows while emphasizing potency control, desensitization readouts, and troubleshooting.
-
α2-AR Agonism in Osteosarcoma Recurrence
2026-08-07
A recent preclinical study tested local delivery of the α2-adrenergic receptor agonist UK14,304 in a thermo-sensitive PLGA-PEG-PLGA hydrogel after osteosarcoma resection. Its findings support an immune-mediated mechanism involving CD8+ T-cell activation, T-cell receptor signaling, and ITGAL-associated regulation rather than direct tumor-cell cytotoxicity.